TY - JOUR T1 - Characteristics of SARS-CoV-2 Positive Individuals in California From Two Periods During Notable Decline in Incident Infection JF - medRxiv DO - 10.1101/2021.05.11.21257008 SP - 2021.05.11.21257008 AU - Lao-Tzu Allan-Blitz AU - Isaac Turner AU - Fred Hertlein AU - Jeffrey D. Klausner Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/12/2021.05.11.21257008.abstract N2 - Despite declining SARS-CoV-2 incidence, continued epidemic monitoring is warranted. We collected SARS-CoV-2 test results from 150 drive-through testing centers across California from two observation periods: February 23rd-March 3rd 2021 and April 15th-April 30th 2021. We assessed SARS-CoV-2 positivity, stratified by Hispanic heritage among sociodemographic characteristics and potential exposures. We analyzed 114,789 test results (5.1% and 2.6% positive during the respective observation periods). Nearly half of all positive tests were among testers reporting a recent exposure (48.8% and 45.3% during the respective observation periods). Those findings may provide insight into evolving local transmission dynamics and support targeted public health strategies.Competing Interest StatementDr. Allan-Blitz served as a consultant for Curative Inc., Fred Hertlein is an employee of Curative Inc., Isaac Turner is a Co-Founder and Chief Information Officer of Curative Inc., and Dr. Klausner is the medical director of Curative Inc.Funding StatementThere was no funding for this project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mass General Brigham institutional review board deemed the analysis of de-identified data did not constitute human subjects research (2020P003530).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is available upon request ER -